Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Glioblastoma

dichlororibofuranosylbenzimidazole has been researched along with Glioblastoma in 2 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dixit, D1
Sharma, V1
Ghosh, S1
Mehta, VS1
Sen, E1
Desbaillets, I1
Diserens, AC1
de Tribolet, N1
Hamou, MF1
Van Meir, EG1

Other Studies

2 other studies available for dichlororibofuranosylbenzimidazole and Glioblastoma

ArticleYear
Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Cell death & disease, 2012, Feb-09, Volume: 3

    Topics: Apigenin; Apoptosis; Brain; Brain Neoplasms; Casein Kinase II; Cell Cycle Checkpoints; Cell Line, Tu

2012
Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma.
    Oncogene, 1999, Feb-18, Volume: 18, Issue:7

    Topics: Animals; Cell Hypoxia; Cobalt; Dactinomycin; Dichlororibofuranosylbenzimidazole; Endothelial Growth

1999